The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Nontuberculous Mycobacterial Infection Market In 2026, And How Will Its Value Evolve By 2030?
The nontuberculous mycobacterial infection market has experienced substantial growth in recent years. It is projected to expand from $14.96 billion in 2025 to $15.87 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.1%. This historical expansion can be attributed to factors such as the high incidence of pulmonary infections, a limited availability of effective therapies, delayed diagnosis of nontuberculous mycobacteria, reliance on conventional antibiotic regimens, and low awareness among clinicians.
The market for nontuberculous mycobacterial infection is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $21.01 billion, demonstrating a compound annual growth rate (CAGR) of 7.3%. This projected growth is largely driven by factors such as the increasing uptake of combination therapies involving macrolides and rifampin, the enhanced availability of aminoglycosides, the development of more personalized treatment strategies, the broadening of hospital and specialty pharmacy infrastructures, and the creation of AI-powered monitoring and diagnostic instruments. Key developments expected during this period involve the greater acceptance of macrolide and rifampin treatments, the increasing application of aminoglycoside-based therapies, the wider adoption of multi-drug regimens, the expanded use of sophisticated diagnostic technologies, and the progressive incorporation of AI for treatment oversight.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp
Which Primary Drivers Are Impacting The Nontuberculous Mycobacterial Infection Market Growth?
The increasing occurrence of chronic obstructive pulmonary disease (COPD) is projected to drive the expansion of the nontuberculous mycobacterial infection market in the future. COPD is defined as a long-term respiratory ailment marked by ongoing and frequently worsening restriction of airflow in the lungs. For individuals suffering from COPD, nontuberculous mycobacterial (NTM) infections are linked to a greater reduction in forced expiratory volume in one second (FEV1) and a higher frequency of exacerbations. COPD can compromise the immune system and harm lung tissue, thereby facilitating NTM bacteria to infect the lungs. As an illustration, Public Health Scotland, a government health agency based in Scotland, reported in September 2024 that in Scotland during 2022/23, the incidence of COPD, determined from hospital admissions and death records, stood at 112.4 cases per 100,000 for females and 109.7 cases per 100,000 for males. Consequently, the increasing prevalence of chronic obstructive pulmonary disease (COPD) fuels the expansion of the nontuberculous mycobacterial infection market.
How Is The Nontuberculous Mycobacterial Infection Market Broken Down By Segment Categories?
The nontuberculous mycobacterial infection market covered in this report is segmented –
1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Macrolides: Azithromycin, Clarithromycin, Erythromycin
2) By Rifampin: Rifampin Monotherapy, Rifampin Combination Therapy, Extended-Duration Rifampin Therapy
3) By Aminoglycoside: Amikacin, Streptomycin, Tobramycin
4) By Other Drug Classes: Fluoroquinolones, Ethambutol, Linezolid, Clofazimine
Which Trends Are Shaping Growth In The Nontuberculous Mycobacterial Infection Market?
Leading companies in the nontuberculous mycobacterial infection market are concentrating on developing advanced solutions, such as boron-based antibiotics, to boost treatment efficacy, overcome drug resistance, and improve patient results. These boron-based antibiotics are small-molecule therapies crafted to inhibit bacterial protein synthesis, providing potent and safer alternatives for persistent infections. For instance, in September 2023, AN2 Therapeutics, a US-based biopharmaceutical company, began enrolment in the Phase 3 portion of its pivotal Phase 2/3 clinical trial for epetraborole in treatment-refractory Mycobacterium avium complex lung disease, after having completed Phase 2 enrolments. Epetraborole, designed for oral administration, showed promise in preclinical studies for treating Mycobacterium abscessus infections, with the objective of decreasing treatment duration, enhancing tolerability, and addressing unmet medical needs in rare and serious infectious lung diseases, thus supporting improved patient outcomes and disease management.
Which Players Are Present In The Nontuberculous Mycobacterial Infection Market Space?
Major companies operating in the nontuberculous mycobacterial infection market are Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin Limited, Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc, Mannkind Corporation, Matinas BioPharma Holdings Inc, Vast Therapeutics Inc, Crestone Inc, AN2 Therapeutics Inc, Revimmune Inc, Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG, RedHill Biopharma Ltd, Shanghai MicuRx Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Cipla Limited, Daiichi Sankyo Company Ltd.
Get The Full Nontuberculous Mycobacterial Infection Market Report:
Which Region Is The Leading Market For The Nontuberculous Mycobacterial Infection Market?
North America was the largest region in the nontuberculous mycobacterial infection market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the nontuberculous mycobacterial infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Nontuberculous Mycobacterial Infection Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Nontuberculous Mycobacterial Infection Market 2026, By The Business Research Company
Waterless Cosmetics Market Report 2026
https://www.thebusinessresearchcompany.com/report/waterless-cosmetics-global-market-report
Mineral Cosmetics Market Report
https://www.thebusinessresearchcompany.com/report/mineral-cosmetics-global-market-report
Vegan Cosmetics Market Report
https://www.thebusinessresearchcompany.com/report/vegan-cosmetics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model